$HNVR

Hanover Bancorp, Inc. /MD

1
0
0
$269K
O'Connor Kevin M
0%
See all $HNVR insider activity →
Med

Hanover Bancorp stock rises on share buyback program approval

Hanover Bancorp (HNVR) shares rose 2% after announcing a $370,000 share buyback program, 5% of outstanding stock, expiring August 17, 2027. The program starts after completing a prior buyback. Raymond James initiated coverage with a Market Perform rating, citing improved profitability but near-term credit risks.

Monday’s insider activity: Notable buys and sells disclosed

Investing.com reported Monday’s SEC Form 4 insider trades for several US-listed firms. Buys included Hanover Bancorp (HNVR) President Kevin O’Connor buying 10,000 shares at $26.88, Protagenic Therapeutics (PTIX) executive chair buying 26,291 shares at $0.1828, and V F Corp (VFC) CEO buying 32,894 shares at ~$14.98. Sales included Snowflake (SNOW) EVP selling 29,986 shares at $300 and Cactus (WHD) leaders selling 86,700 shares each at $57.618.

HNVR sentiment & insider activity

Over the past 7 days, alphai's AI scored 1 news story mentioning HNVR (Hanover Bancorp, Inc. /MD). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent HNVR coverage spans insider activity, corporate actions and financial news.

In the last 30 days, HNVR insiders filed 1 SEC Form 4 transaction — 1 purchase ($269K) and no sales. The most active reporter was O'Connor Kevin M, President, with 1 filing.

What's driving HNVR

  • The buyback signals confidence and may support the stock price in the near term.

    investing.com · Aug 26, 2026

  • Management buying near the stock’s 52-week high can support near-term sentiment, though it is not a fundamental catalyst by itself.

    investing.com · Aug 4, 2026

  • This is a disclosed insider buy, but it is not a new fundamental catalyst like earnings or guidance.

    SEC EDGAR · Aug 3, 2026

  • Q2 results show improving profitability via higher net interest income and margin expansion, alongside capital return via a declared quarterly cash dividend.

    SEC EDGAR 8-K · Jul 23, 2026

  • Board-level leadership change with defined compensation terms, likely a modest sentiment catalyst rather than a fundamental earnings reset.

    SEC EDGAR 8-K · Jul 20, 2026

alphai scores every news story that mentions HNVR with an AI model for sentiment and relevance, and aggregates insider trades from Hanover Bancorp, Inc. /MD's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $HNVR

Score

Monday’s insider activity: Notable buys and sells disclosed

Investing.com reported Monday’s SEC Form 4 insider trades for several US-listed firms. Buys included Hanover Bancorp (HNVR) President Kevin O’Connor buying 10,000 shares at $26.88, Protagenic Therapeutics (PTIX) executive chair buying 26,291 shares at $0.1828, and V F Corp (VFC) CEO buying 32,894 shares at ~$14.98. Sales included Snowflake (SNOW) EVP selling 29,986 shares at $300 and Cactus (WHD) leaders selling 86,700 shares each at $57.618.

$HNVRMed

Hanover Bancorp, Inc. /MD (HNVR): Results of Operations and Financial Condition

Hanover Bancorp, Inc. /MD (HNVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hnvr-20260723xex99d1.htm EX-99.1 Exhibit 99.1 ​ ​ FOR IMMEDIATE RELEASE Investor and Press Contact: Lance P. Burke Chief Financial Officer (516) 548-8500 ​ ​ Hanover Bancorp, Inc. Reports Second Quarter 2026 Results Highlighted by Increased Net Interest Income and Margi

$HNVRLow

Hanover Bancorp, Inc. /MD (HNVR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Hanover Bancorp, Inc. /MD (HNVR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Hanover Bancorp, Inc. /MD_July 20, 2026 Hanover Bancorp, Inc. /MD 0001828588 false 0001828588 2026-07-20 2026-07-20 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ​ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

Related tickers